What therapies are on the horizon for HER2 positive breast cancer?

Giulia Viale, Stefania Morganti, Emanuela Ferraro, Paola Zagami, Antonio Marra, Giuseppe Curigliano

Research output: Contribution to journalReview articlepeer-review


Introduction: Despite dramatic improvements in survival achieved with currently available anti-HER2 agents, HER2-positive metastatic breast cancer remains an almost invariably deadly disease, with primary or acquired resistance to HER2-directed agents developing during treatment. Many efforts are focused on identifying new agents that may more effectively inhibit HER2 signaling and on possible combination strategies. Areas covered: This review summarizes the landscape of drugs under development for HER2-positive metastatic breast cancer, as antibody-drug conjugates, monoclonal anti-HER2 antibodies, bispecific antibodies, or novel tyrosine kinase inhibitors. Moreover, available data for possible combination of anti-HER2 drugs and different agents, as immunotherapy, PI3K/mTOR inhibitors, CDK4/6 inhibitors currently under evaluation are reviewed. These strategies may overcome mechanisms of resistance and further improve patient outcomes. Expert opinion: Identification of valuable predictive biomarkers is needed to better inform choice of treatment sequence for the individual patient and limit the financial toxicity of these agents.

Original languageEnglish
Pages (from-to)811-822
Number of pages12
JournalExpert Review of Anticancer Therapy
Issue number9
Publication statusPublished - Sep 2 2019


  • antibody drug conjugates
  • DS-8201a
  • HER2 positive advanced breast cancer
  • immunotherapy
  • margetuximab
  • new drug development
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'What therapies are on the horizon for HER2 positive breast cancer?'. Together they form a unique fingerprint.

Cite this